ABSTRACT
INTRODUCTION While higher socioeconomic factors (SEF) and cognitive performance (CP) have been associated with reduced Alzheimer’s disease (AD) risk, recent evidence highlighted that these factors may have opposite effects on family history of AD (FHAD).
METHODS Leveraging data from the UK Biobank (N=448,100) and the All of Us Research Program (N=240,319), we applied generalized linear regression models, polygenic risk scoring (PRS), and one-sample Mendelian randomization (MR) to test the sex-specific SEF and CP associations with AD and FHAD.
RESULTS Observational and genetically informed analyses highlighted that higher SEF and CP were associated with reduced AD and sibling-FHAD, while these factors were associated with increased parent-FHAD. We also observed that population minorities may present different patterns with respect to sibling-FHAD vs. parent-FHAD. Sex differences in FHAD associations were identified in ancestry-specific and SEF PRS and MR results.
DISCUSSION This study contributes to understanding the sex-specific relationships linking SEF and CP to FHAD, highlighting the potential role of reporting, recall, and surviving-related dynamics.
Competing Interest Statement
RP is paid for his editorial work on the journal Complex Psychiatry and received a research grant outside the scope of this study from Alkermes. APM reports grants for clinical trials from Genentech, Eli Lilly, and Janssen Pharmaceuticals. CHvD reports consulting fees from Eisai, Roche, Ono, and Cerevel and grants for clinical trials from Biogen, Eli Lilly, Eisai, Janssen, Roche, Genentech, UCB, and Cerevel. The remaining authors declare that they have no competing interests.
Funding Statement
The authors acknowledge support from the National Institutes of Health (R33 DA047527; RF1 MH132337, 5K99AG078503-02), One Mind, Alzheimer's Association Research Fellowship (AARF-22-967171), American Foundation for Suicide Prevention (PDF-1-022-21), and the Yale Franke Program in Science and Humanities. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023163; Communications and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners: 1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2OD025276.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The UK Biobank has approval from the North-West multi-centre research ethics committee as a Research Tissue Bank approval. The All of Us Research Program was approved by the All of Us Institutional Review Board. All participants in the two studies provided informed consent at recruitment. The data used in this study were obtained through an application reference No. 58146 for the UK Biobank and through an approved data use agreement for the All of Us Research Program.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
DATA AVAILABILITY
The UKB individual data could be obtained by applying on the website (http://www.ukbiobank.ac.uk/). The UKB GWAS data could be downloaded from the Neale Lab (http://www.nealelab.is/uk-biobank) and Oxford Brain Imaging Genetics Server (https://open.win.ox.ac.uk/ukbiobank/big40/). The AoU data in this article were accessed from the All of Us Curated Data Repository version 7 (https://www.researchallofus.org). PRS was calculated using PRScs (https://github.com/getian107/PRScs) and PLINK 1.9 (https://www.cog-genomics.org/plink/1.9/). One-sample MR analyses were performed using OneSampleMR (https://github.com/remlapmot/OneSampleMR) and ivreg (https://github.com/zeileis/ivreg/).
